The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL			
OMB Number:	3235- 0076		
Estimated average burden			
hours per response:	4.00		

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	None	Entity Type	
0001411685		terprises, Ltd.	X Corporation	
Name of Issuer	Excumper En	cerprises, Etc.	Limited Partnership	
VistaGen Therapeutics, Inc.			Limited Liability Company	V
Jurisdiction of			General Partnership	/
Incorporation/Organizati	on		Business Trust	
NEVADA			Other (Specify)	
Year of Incorporation/	Organization			
X Over Five Years Ago				
Within Last Five Years (Specif	y Year)			
Yet to Be Formed				
2. Principal Place of Business and	Contact Information			
Name of Iss	uer			
VistaGen Therapeutics, Inc.				
Street Addre	ess 1		Street Address 2	
343 Allerton Avenue				
City St	ate/Province/Country	ZIP/Posta	Code Phone Number of Issuer	
South San Francisco CAI	LIFORNIA	94080	650-577-3600	
3. Related Persons				
Last Name	Firs	t Name	Middle Name	
Singh	Shawn		К.	
Street Address 1	Street .	Address 2		
343 Allerton Avenue				
City	State/Prov	vince/Country	ZIP/PostalCode	
South San Francisco	CALIFORNIA		94080	
Relationship: X Executive Office	er X Director Promote	er		
Clarification of Response (if Nece	ssary):			
Last Name	Firs	t Name	Middle Name	
Dotson	Jerrold		D.	
Street Address 1		Address 2		
343 Allerton Avenue				
City	State/Prov	vince/Country	ZIP/PostalCode	
South San Francisco	CALIFORNIA	-	94080	

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name		Middle Name
Snodgrass	H.	Ralph	
Street Address 1	Street Address 2		
343 Allerton Avenue City	State/Province/Country		ZIP/PostalCode
South San Francisco	CALIFORNIA	94080	
Relationship: X Executive Officer		51000	
Clarification of Response (if Necess			
Last Name	First Name	S.	Middle Name
Saxe Street Address 1	Jon Street Address 2	5.	
343 Allerton Avenue	Street Address 2		
City	State/Province/Country		ZIP/PostalCode
South San Francisco	CALIFORNIA	94080	
Relationship: Executive Officer 2	X Director Promoter		
Clarification of Response (if Necess	ary):		
Last Name	First Name		Middle Name
Underdown	Brian	J.	When the
Street Address 1	Street Address 2		
343 Allerton Avenue			
City	State/Province/Country		ZIP/PostalCode
South San Francisco	CALIFORNIA	94080	
Relationship: Executive Officer 2	X Director Promoter		
Clarification of Response (if Necess	ary):		
Last Name	First Name		Middle Name
Gin	Jerry	В.	
Street Address 1	Street Address 2		
343 Allerton Ave.			
City	State/Province/Country		ZIP/PostalCode
South San Francisco	CALIFORNIA	94080	
Relationship: Executive Officer 2	X Director Promoter		
Clarification of Response (if Necess	ary):		
Last Name	First Name		Middle Name
Smith	Mark	А.	
Street Address 1	Street Address 2		
343 Allerton Ave.			
City	State/Province/Country		ZIP/PostalCode
South San Francisco	CALIFORNIA	94080	
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Necess	ary):		
Last Name	First Name		Middle Name
McPartland	Mark	А.	
Street Address 1	Street Address 2		
343 Allerton Ave.			
A 1737	State Durante Comment		7ID/DectalCode
City South San Francisco	State/Province/Country CALIFORNIA	94080	ZIP/PostalCode

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Cunningham	Ann	К.
Street Address 1	Street Address 2	
343 Allerton Ave.		
City	State/Province/Country	ZIP/PostalCode
South San Francisco	CALIFORNIA	94080
Relationship: Executive Officer X	Director Promoter	

Clarification of Response (if Necessary):

4. Industry Group

Agriculture		Health Care	Retailing
Banking & Financi	al Services	Biotechnology	Restaurants
Commercial Ban	ıking	Health Insurance	Technology
Insurance Investing		Hospitals & Physicians	Computers
Investment Bank	king	X Pharmaceuticals	Telecommunications
Pooled Investme	ent Fund	Other Health Care	Other Technology
Is the issuer reginant investment control the Investment Control the Investment Control Act of 1940?	ompany under	Manufacturing Real Estate Commercial	Travel Airlines & Airports Lodging & Conventions
Yes	No	Construction	Tourism & Travel Services
Other Banking 8	k Financial Services	REITS & Finance	Other Travel
Business Services		Residential	Other
Energy		Other Real Estate	
Coal Mining			
Electric Utilities			
Energy Conserva	ation		
Environmental S	Services		
Oil & Gas			
Other Energy			
5. Issuer Size			

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Investment Company Act Section 3(c)

Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5)	Section Section Section Section Section	3(c)(2) 3(c)(3) 3(c)(4) 3(c)(5) 3(c)(6)	Section $3(c)(9)$ Section $3(c)(10)$ Section $3(c)(11)$ Section $3(c)(12)$ Section $3(c)(13)$ Section $3(c)(14)$		
7. Type of Filing					
X New Notice Date of First Sale 2020-01-24 Amendment	First Sale Ye	et to Occur			
8. Duration of Offering					
Does the Issuer intend this offering to last more the	nan one year	? Yes X No			
9. Type(s) of Securities Offered (select all that app	ply)				
 Equity Debt X Option, Warrant or Other Right to Acquire And Security to be Acquired Upon Exercise of Opti Other Right to Acquire Security 10. Business Combination Transaction Is this offering being made in connection with a b a merger, acquisition or exchange offer? Clarification of Response (if Necessary): 11. Minimum Investment Minimum investment accepted from any outside in 12. Sales Compensation Recipient 	on, Warrant ousiness com	Tenant-in y Mineral F or Other (de bination transac		,	
(Associated) Broker or Dealer X None		(Associated) B Number	roker or Dealer CRD	X None	
Street Address 1			Street Address 2		
City		State/Province/	Country		ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All Statesâ€∏ or check individual States	All States	Foreign/non-	US		
13. Offering and Sales Amounts					
Total Offering Amount\$2,750,000 USDorTotal Amount Sold\$2,750,000 USDTotal Remaining to be Sold\$0 USDorClarification of Response (if Necessary):	Indefinite Indefinite				

Clarification of Response (if Necessary):

Represents the aggregate gross proceeds from investors in connection with Issuer's registered direct offering of common stock and concurrent private placement of warrants, which were issued to investors for a single purchase price.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

0	
3	

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
VistaGen Therapeutics, Inc.	/s/ Jerrold D. Dotson	Jerrold D. Dotson	Chief Financial Officer	2020-01-31

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a

result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.